News
APLS
69.36
+6.03%
3.95
BRIEF-Apellis Announces 24-Month Phase 3 Post HOC Results Showing Treatment With Pegcetacoplan Led To Preservation Of Function In High-Risk Areas Of The Retina In Patients With Geographic Atrophy
BRIEF-Apellis Announces 24-Month Phase 3 Post HOC Results Showing Treatment With Pegcetacoplan Led To Preservation Of Function In High-Risk Areas Of The Retina In Patients With Geographic Atrophy
Reuters · 7h ago
BRIEF-Apellis Reports Presentations Of Data From Phase 3 Of Pegcetacoplan In Geographic Atrophy
BRIEF-Apellis Reports Presentations Of Data From Phase 3 Of Pegcetacoplan In Geographic Atrophy
Reuters · 17h ago
Apellis Pharmaceuticals Announces New Presentation Time at the Bank of America Global Healthcare Conference
WALTHAM, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced updated timing for its fireside chat at an upcoming investor conference hosted by ...
GlobeNewswire · 09/12 20:05
Insider Sell: Apellis Pharmaceuticals
Insider Sell: Apellis Pharmaceuticals
MT Newswires · 09/12 17:01
Wedbush Maintains Neutral on Apellis Pharmaceuticals, Raises Price Target to $67
Wedbush analyst Laura Chico maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Neutral and raises the price target from $55 to $67.
Benzinga · 09/12 13:48
Wedbush Raises Price Target on Apellis Pharmaceuticals to $67 From $55, Sees Increased Probability of Approval for Pegcetacoplan in Geographic Atrophy; Neutral Kept
Wedbush Raises Price Target on Apellis Pharmaceuticals to $67 From $55, Sees Increased Probability of Approval for Pegcetacoplan in Geographic Atrophy; Neutral Kept
MT Newswires · 09/12 07:55
Apellis (APLS) Up More Than 60% in Past 3 Months: Here's Why
Apellis' (APLS) marketed drug, Empaveli, approved for treating paroxysmal nocturnal hemoglobinuria is driving revenues. The drug's label expansion studies also hold promise.
Zacks · 09/09 13:24
Where Apellis Pharmaceuticals Stands With Analysts
Within the last quarter, Apellis Pharmaceuticals (NASDAQ:APLS) has observed the following analyst ratings:
Benzinga · 09/08 17:09
Stifel Maintains Buy Rating for Apellis Pharmaceuticals: Here's What You Need To Know
Stifel has decided to maintain its Buy rating of Apellis Pharmaceuticals (NASDAQ:APLS) and raise its price target from $60.00 to $65.00. Shares of Apellis Pharmaceuticals are trading up 2.69% over the last 24 hours, at $65.98 per share.
Benzinga · 09/08 16:22
Moderna To $165? Plus This Analyst Cuts PT On FedEx
Deutsche Bank raised the price target on Moderna, Inc. (NASDAQ: MRNA) from $155 to $165. Deutsche Bank analyst Emmanuel Papadakis also upgraded the stock from Hold to Buy. Moderna shares rose 2.8% to trade at $138.70 on Thursday.
Benzinga · 09/08 13:46
Stifel Maintains Buy on Apellis Pharmaceuticals, Raises Price Target to $65
Stifel analyst Annabel Samimy maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and raises the price target from $60 to $65.
Benzinga · 09/08 12:08
Stifel Nicolaus Adjusts Price Target on Apellis Pharmaceuticals to $65 From $60, Keeps Buy Rating
Stifel Nicolaus Adjusts Price Target on Apellis Pharmaceuticals to $65 From $60, Keeps Buy Rating
MT Newswires · 09/08 11:15
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved the grant of equity awards to 64 new employees with a gra...
GlobeNewswire · 09/07 20:05
Apellis gains as FDA says AdCom unnecessary for eye disease candidate
The commercial-stage biotech Apellis Pharmaceuticals (NASDAQ:A...
Seekingalpha · 09/07 19:07
Why Is Apellis Pharmaceuticals, Inc. (APLS) Down 9.8% Since Last Earnings Report?
Apellis Pharmaceuticals, Inc. (APLS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 09/07 15:30
B. Riley Downgrades IVERIC bio to Sell from Neutral After 'Disappointing' Data Which Reaffirms View of Zimura as Non-Distinguishable to Apellis' Pegcetacoplan; Lowers PT to $8 from $12
B. Riley Downgrades IVERIC bio to Sell from Neutral After 'Disappointing' Data Which Reaffirms View of Zimura as Non-Distinguishable to Apellis' Pegcetacoplan; Lowers PT to $8 from $12
MT Newswires · 09/07 08:52
Iveric drives Apellis lower as Street reacts to Phase 3 data for GA candidate
Iveric bio (NASDAQ:ISEE), have sparked volatility in rival biote...
Seekingalpha · 09/06 18:47
Why Minerva Neurosciences Shares Traded Higher By Over 66%; Here Are 78 Biggest Movers From Yesterday
Gainers Minerva Neurosciences, Inc. (NASDAQ: NERV) shares gained 66.5% to close at $7.51 after Point72 Asset Management reported an 8.8% passive stake in the company.
Benzinga · 08/25 09:18
More
Webull provides a variety of real-time APLS stock news. You can receive the latest news about Apellis Pharmace through multiple platforms. This information may help you make smarter investment decisions.
About APLS
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company that is focused on developing therapeutic compounds to treat disease through the inhibition of the complement system. The Company is developing pegcetacoplan with Sobi for systemic administration in several indications, including paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy, immune complex membranoproliferative glomerulonephritis, amyotrophic lateral sclerosis, cold agglutinin disease, and hematopoietic stem cell transplantation thrombotic microangiopathy. The Company's advanced clinical programs targeting component 3 with Phase III clinical trials of its lead product candidate, pegcetacoplan, in multiple indications. Pegcetacoplan is a conjugate of a compstatin analogue, formulated both for ophthalmological administration by injections directly into the eye, and systemic administration by subcutaneous injection, which is an injection into the tissue under the skin.